Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04530058 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effects of Metformin on Morbidity and Mortality in Elderly Patients

Study acronym: MET-ELD
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Mar 2024 to Nov 2024
    • Site contact updated
    v7
  2. Primary completion date: Aug 2027 to Mar 2028
    • Start date: Aug 2023 to Mar 2024
    • Study completion date: Aug 2028 to Mar 2029
    v6
  3. Re-verified, no change to tracked fieldsv5
  4. Lead sponsor: Sunnybrook Health Sciences Centre to Hamilton Health Sciences Corporationv4 Show 7 more changesShow less
    • Primary completion date: Oct 2023 to Aug 2027
    • Start date: Jan 28, 2021 to Aug 2023
    • Primary endpoints revised (9)
    • Trial status: Recruiting to Not Yet Recruiting
    • Study completion date: Apr 2024 to Aug 2028
    • Study site revised
    • Eligibility criteria expanded, about 4 words
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2020 to Jan 28, 2021
    • Study sites: 0 to 1
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Elderly patients have an increased susceptibility to burns and a substantial mortality that has not significantly changed over the last three decades. Elderly burn patients not only have an augmented response to burn but also express a prolonged hypermetabolic response.Glucose metabolism with insulin resistance is a hypermetabolic response pathway that profoundly affects post-burn outcomes. The aim if this study is to determine whether metformin can improve morbidity and mortality in elderly burn patients. The investigators hypothesize that metformin will improve clinical outcomes and mortality of elderly burn patients by alleviating the complex inflammatory and hypermetabolic responses after burn.
Trial Details
NCT Number NCT04530058
Lead Sponsor Hamilton Health Sciences Corporation
Conditions
(from sponsor)		 Burns
Related terms Burns
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov